Navigation Links
Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
Date:12/14/2011

t facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis.  Certain unusual or non-recurring items that management does not believe affect the Company's basic operations do not meet the GAAP definition of unusual or non-recurring items.  Non-GAAP net loss and non-GAAP loss per share are not, and should not be viewed as a substitute for similar GAAP items.  We define non-GAAP diluted loss per share amounts as non-GAAP net loss divided by the weighted average number of diluted shares outstanding.  Our definition of non-GAAP net loss and non-GAAP diluted loss per share may differ from similarly named measures used by others.

Full details of the Company's financial results will be available in the Company's Form 10-Q at www.championsoncology.com.

About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.  The Company's Tumorgraft™ Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts™, in a manner that preserves the biological characteristics of the original human tumor.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions ("POS") in which physicians and patients looking for information help guide the development of personalized treatment plans, and Translational Oncology Solutions ("TOS") in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs. The Compan
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
4. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
5. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
6. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
7. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
8. Champions Biotechnology Awarded $1.46 million in Grants
9. Champions CFO Resigns
10. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
11. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... Research and Markets ( ... "Global Smart Wearable Healthcare Devices and Services ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The analysts forecast ... market to grow at a CAGR of 30.42% ... covers the present scenario and the growth prospects ...
(Date:3/26/2015)... Md. , March 26, 2015  RegeneRx Biopharmaceuticals, ... it has received a patent acceptance notice from the ... 4 (TB4) to prevent or reduce tissue damage caused ... the case when cardiac vessels are opened after a ... when treating stroke victims. Damage can be ...
(Date:3/26/2015)...  Becton, Dickinson and Company (NYSE: BDX ) ... exchange all validly tendered and accepted notes of the ... subsidiary of BD, for notes to be issued by ... Statement on Form S-4 (the "Registration Statement") relating to ... the Securities and Exchange Commission ("SEC") on March 26, ...
Breaking Medicine Technology:Global Smart Wearable Healthcare Devices and Services Market 2015-2019 WITH Apple, At&T, Ee, Google, Samsung, Sprint, Telefonica & T-Mobile Dominating 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3Becton, Dickinson and Company to Commence Exchange Offers 2Becton, Dickinson and Company to Commence Exchange Offers 3Becton, Dickinson and Company to Commence Exchange Offers 4Becton, Dickinson and Company to Commence Exchange Offers 5
... 7, 2011 Intellect Neurosciences, Inc. (OTCBB: ILNS) a ... and multiple licenses with major pharmaceutical companies covering products ... Dr. Daniel Chain, Ph.D., Chairman and CEO will be ... Dr. Chain will be discussing the state of the ...
... The U.S. Food and Drug Administration and the ... a "parallel review" pilot program for concurrent review of ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... today, issued procedures for voluntary participation and guiding principles ...
Cached Medicine Technology:Intellect Neurosciences CEO to be Featured on Wall Street Reporter 2FDA, CMS Launch Pilot Program for Voluntary Parallel Review of Innovative Devices 2
(Date:3/26/2015)... Dr. Rod J. Rohrich, who served as ... and has trained over 6500 surgeons through these meetings ... medicine (EBM), that is, the optimization of decision making ... often hear from rhinoplasty surgeons who describe ... not trying to stifle these discussions, we do want ...
(Date:3/26/2015)... UC Davis will establish a prestigious, leading-edge center ... A Silvio O. Conte Center for Basic or Translational ... the United States. , The center will be funded ... of Mental Health, which will allow UC Davis’ Conte ... of schizophrenia may be dysregulation of immune molecules that ...
(Date:3/26/2015)... Scott Sullivan and Frank DellaCroce, Co-Founders of the ... St. Charles Surgical Hospital (SCSH) in New ... Oncologist Dr. William Karl Ordoyne has joined their highly ... oncologist Alan Stolier, M.D., FACS and the team of ... M.D., FACS; Chris Trahan, M.D., FACS; M. Whitten Wise, ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Building ... of continuing medical education, the Cardiometabolic Risk ... Medicine at Tulane University are proud to ... Medicine. The interdisciplinary program , which ... credential, is designed for physicians, nurse practitioners, physician ...
(Date:3/26/2015)... March 26, 2015 Visiting Nurse ... their 18th annual gala fundraiser, Lighting the Way, Brightening ... p.m. at The Madison Hotel in Morristown, NJ. ... entertainment by renowned musician Rio Clemente, delightful cuisine, an ... and Dave Hertzel. Additionally, two prestigious awards will be ...
Breaking Medicine News(10 mins):Health News:Dr. Rod Rohrich Explores Evidence Based Innovations and Safety at the 32nd Annual Dallas Rhinoplasty Symposium 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 3Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 4Health News:Surgical Oncologist Joins Center for Restorative Breast Surgery and St. Charles Surgical Hospital 2Health News:Surgical Oncologist Joins Center for Restorative Breast Surgery and St. Charles Surgical Hospital 3Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 3Health News:Morristown VNA Fundraiser to Honor Distinguished Community Members 2
... Human ... , , ... (PRWEB) April 6, 2010 -- Human Touch , the U.S. market leader of innovative ... the World Federation of Chiropractic (WFC) for its massage chairs as a valid supplement to ...
... (short for sarcoma) is a family of proto-oncogenic tyrosine ... the most common malignant cancer in children. Src represents ... A recent study shows that pyrazolo-[3,4-d]pyrimidine-derivatives, designed to ... cell cycle and causing cancer cell death in medulloblastoma. ...
... Swedish medical university Karolinska Institutet provides evidence that basic ... that also exist in the most primitive vertebrates, such ... an investigation into the limbic striatum, one of the ... to learn movements, consciously and unconsciously, through repetition. ...
... ... massage. There are many other massages and spa services that customers can enjoy ... ... Envy’s New Jersey franchise group ( http://www.massageenvy.com/regions/NJ/Northern-New-Jersey.aspx ), a subsection of franchisees of ...
... and sedatives up 65 percent in U.S., study finds ... by accidental and intentional abuse of prescription sedatives, tranquilizers ... last decade, new research reveals. , Hospital stays from ... Percocet) and sedatives (such as Valium and Ativan) jumped ...
... ... ... Noni International (TNI) announced a new quarter of a million dollar challenge to all ... industry will measure up to Tahitian Noni Bioactive Beverages., , , , ,Tahitian Noni International ...
Cached Medicine News:Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 2Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 3Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 4Health News:Human Touch Massage Chairs Receive Exclusive Endorsement from World Federation of Chiropractic 5Health News:New pyrimidine compounds may lead to improved treatments for childhood brain cancer 2Health News:Unconscious learning uses old parts of the brain 2Health News:Massage Envy New Jersey offers $49, 1-Hour Therapeutic Massage 2Health News:Prescription Drug Abuse Sending More to Hospitals 2Health News:Prescription Drug Abuse Sending More to Hospitals 3Health News:Quarter of a Million Dollar Superfruit Challenge Announced 2
Used as a percutaneous entry needle to introduce wire guides. The coaxial design reduces potential A.V. malformations. Supplied sterile in peel-open packages. Intended for one-time use....
Used under fluoroscopy for initial location and positioning of the renal collecting system throughout a percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
Used under fluoroscopy for initial location and positioning of the renal collecting system throughout a percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
Medicine Products: